Total Funding
55
52
Total FundingVenture - Series Unknown raised
Growth Score 55 in past quarter
-4 pts
Heat Score 52 in past quarter
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
121884
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures.
Acquired by 
Absci
Deniz Kural: CEO & FounderPast Role: Seven Bridges, Co-Founder & CEO
About the Company
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the
most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses.
It was founded in 2017 and is based in Cambridge, Massachusetts.